Wedbush Raises Price Target on Rezolute to $10 From $6, Keeps Outperform Rating
Wedbush Securities has increased its price target for Rezolute, Inc. from $6 to $10 while maintaining an 'Outperform' rating.
Stocks · News reference
Rezolute released an investor presentation detailing its clinical progress for ersodetug, including a cash runway extending through Q1 2028 and updates on its hyperinsulinism programs.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wedbush Securities has increased its price target for Rezolute, Inc. from $6 to $10 while maintaining an 'Outperform' rating.
Filed: 2026-11-16 AccNo: 0001104659-26-127490 Size: 607 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Rezolute achieves its Phase 3 primary endpoint for ersodetug in tumor hyperinsulinism and prices a $100 million equity offering.
Rezolute, Inc. announced the pricing of an underwritten offering expected to raise approximately $100 million in gross proceeds.
Rezolute, Inc. reported that its Phase 3 upLIFT study of ersodetug for the treatment of tumor hyperinsulinism has achieved its primary efficacy endpoint.
Rezolute, Inc. announced its financial results for the first quarter ended September 30, 2026, and provided an update on its clinical programs.